Joseph Echevarria Purchases Pfizer Shares

Joseph Echevarria, a notable insider, purchased 1,904 shares of Pfizer Inc. (NYSE: PFE) on June 26, 2026. The shares were bought at an average price of $24.29, amounting to a total value of $46,248.16. This transaction was not part of a pre-planned trading program.

Other Institutional Activity in Pfizer

Several major institutional investors have recently adjusted their stakes in Pfizer. BlackRock, Inc. increased its holdings by 5,195,022 shares, bringing its total to 498,257,550 shares valued at approximately $13.99 billion, marking a 1.1% increase. Vanguard Capital Management LLC opened a new position with 369,430,012 shares, valued at about $10.37 billion. State Street Corp added 1,144,701 shares, totaling 301,589,865 shares worth approximately $8.47 billion, a 0.4% increase. Geode Capital Management, LLC grew its position by 3,369,661 shares to 133,561,742 shares valued at $3.74 billion, a 2.6% increase.

Pfizer Inc. Stock Down 14.4%

Shares of Pfizer Inc. traded near $24.37 on Wednesday. The company, which operates in the healthcare sector, boasts a market capitalization of roughly $138.4 billion. Pfizer has a P/E ratio of 18.54 and a forward P/E of 8.59. Its stock has seen a 52-week low of $23.11 and a high of $28.75, with a 50-day moving average of $25.97 and a 200-day moving average of $25.87. The company maintains a current ratio of 1.25 and a quick ratio of 0.85, with a debt-to-equity ratio of 71.60.

Recent Earnings

Pfizer reported revenue of $63.32 billion, with a revenue growth rate of 5.4%. The company achieved an earnings per share (EPS) of $1.31, a net margin of 11.83%, and a return on equity (ROE) of 8.31%. The next earnings report is scheduled for August 4, 2026.

Dividend

Pfizer offers an annual dividend rate of $1.72, yielding 7.08%. The company's dividend payout ratio stands at 131.3%.

Insider Buying and Selling at Pfizer Inc.

On June 26, 2026, several insiders, including Joseph Echevarria, James Quincey, Cyrus Taraporevala, Shantanu Narayen, Mortimer Buckley, and James Smith, purchased Pfizer shares. Each transaction involved buying shares at an average price of $24.29, with the number of shares ranging from 1,544 to 2,059.

Analysts Set New Price Targets

On April 29, 2026, Citigroup maintained its hold rating on Pfizer with a price target of $27. CICC initiated coverage with a buy rating and a target of $33 on April 16. Other firms like UBS and Morgan Stanley have maintained hold ratings with targets of $27 and $28, respectively. The consensus among 27 analysts is a buy, with a mean price target of $29.15.

About Pfizer Inc.

Pfizer Inc., headquartered in New York, is a leading global biopharmaceutical company. It develops, manufactures, and sells a wide range of medicines and vaccines. The company operates through segments like Biopharma, PC1, and Pfizer Ignite. Under CEO Dr. Albert Bourla, Pfizer employs around 75,000 people worldwide, focusing on areas such as internal medicine, oncology, and rare diseases.

Bottom Line

Joseph Echevarria's purchase of Pfizer shares highlights ongoing insider interest in the company. With a solid market position and active institutional participation, Pfizer remains a key player in the healthcare sector. As a reminder, insider transactions are reported after the fact and may not reflect the current position of the insider.